Literature DB >> 26777410

Bilateral low frequency rTMS of the primary motor cortex may not be a suitable treatment for levodopa-induced dyskinesias in late stage Parkinson's disease.

Anja Flamez, Ann Cordenier, Sylvie De Raedt, Véronique Michiels, Sara Smetcoren, Annick Van Merhaegen-Wieleman, Eva Parys, Jacques De Keyser, Chris Baeken.   

Abstract

BACKGROUND: In late stage Parkinson patients there is an unmet need for new treatments to adequately control motor complications, especially dyskinesias. In several preliminary studies, it has been suggested that applying unilateral low-frequency repetitive transcranial magnetic stimulation (LF rTMS), delivered at the primary motor cortex (MC) or the supplementary motor area (SMA), may reduce levodopa-induced dyskinesias (LID), either in a single or a multiple session stimulation protocol. In our current clinical research, we examined whether single or multiple (accelerated) sham-controlled bilateral LF rTMS session(s) applied to the primary motor cortices are able to reduce levodopa-induced dyskinesias in patients with advanced Parkinson's disease.
METHODS: During a levodopa challenge test, we first investigated the effect of a single sham-controlled session of LF rTMS (1 Hz) to both left and right primary motor cortical areas on dyskinesias and motor function in nine late-stage Parkinson patients. In a second study, patients were assigned to a five day sham-controlled bilateral motor cortex cross-over accelerated LF rTMS protocol and effects on dyskinesias, motor and executive function and emotional status were assessed.
RESULTS: We found no significant clinical change in levodopa-induced dyskinesias and motor function with either stimulation protocol.
CONCLUSIONS: One or multiple bilateral LF rTMS session(s) applied to the primary motor cortex were unable to reduce levodopa-induced dyskinesias in late-stage Parkinson patients.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26777410     DOI: 10.1016/j.parkreldis.2015.11.009

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  7 in total

1.  Transcranial Non-Invasive Brain Stimulation in Parkinson's Disease Patients with Dyskinesias. Where is the Optimal Target?

Authors:  Antonio Cerasa; Ignacio Obeso; Michele Dileone; Aldo Quattrone
Journal:  Cerebellum       Date:  2017-02       Impact factor: 3.847

2.  Repetitive transcranial magnetic stimulation therapy for motor recovery in Parkinson's disease: A Meta-analysis.

Authors:  Changxia Yang; Zhiwei Guo; Haitao Peng; Guoqiang Xing; Huaping Chen; Morgan A McClure; Bin He; Lin He; Fei Du; Liangwen Xiong; Qiwen Mu
Journal:  Brain Behav       Date:  2018-09-28       Impact factor: 2.708

3.  Repetitive Transcranial Magnetic Stimulation Does Not Improve the Sequence Effect in Freezing of Gait.

Authors:  Jinghong Ma; Linlin Gao; Taomian Mi; Junyan Sun; Piu Chan; Tao Wu
Journal:  Parkinsons Dis       Date:  2019-06-04

Review 4.  Novel targeted therapies for Parkinson's disease.

Authors:  Theodora Ntetsika; Paraskevi-Evita Papathoma; Ioanna Markaki
Journal:  Mol Med       Date:  2021-02-25       Impact factor: 6.354

5.  Safety and Tolerability of Accelerated Low-Frequency Repetitive Transcranial Magnetic Stimulation Over the Primary Motor Cortex-A Pilot Study.

Authors:  Melina Engelhardt; Jana Kimmel; Giovanni Raffa; Alfredo Conti; Thomas Picht
Journal:  Front Neurosci       Date:  2022-03-18       Impact factor: 4.677

6.  Quantitative Electroencephalography Characteristics for Parkinson's Disease: A Systematic Review.

Authors:  Lívia Shirahige; Marina Berenguer-Rocha; Sarah Mendonça; Sérgio Rocha; Marcelo Cairrão Rodrigues; Kátia Monte-Silva
Journal:  J Parkinsons Dis       Date:  2020       Impact factor: 5.568

7.  Motor recovery and antidepressant effects of repetitive transcranial magnetic stimulation on Parkinson disease: A PRISMA-compliant meta-analysis.

Authors:  Shuqian Li; Rui Jiao; Xiaomei Zhou; Shangjie Chen
Journal:  Medicine (Baltimore)       Date:  2020-05       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.